Management of Primary Brain Tumors in the Molecular Era and Building and Refining a Radiosurgery Program (PRO 07)
This activity discusses many challenging topics in the management of primary and metastatic tumors to the brain. For primary brain tumors, the primary focus will be on molecular profiling of primary brain tumors and its effect on management options of patients. Treatment planning and dosing techniques for patients with common primary malignant brain tumors are also reviewed. Management of patients with multiple and large brain metastases will focus on SRS versus whole brain radiation, when to biopsy for tissue diagnosis, and selection of fractionation and radiation dose. The activity will also feature a community expert in radiosurgery who will provide education on the logistics of developing and improving a radiosurgery program.
This activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, pathologists, radiation therapists, radiation dosimetrists and residents.
Upon completion of this live activity, participants should be able to do the following:
- Incorporate information from this activity to improve the management of primary and metastatic brain tumors.
- Return to their teams with techniques to improve their radiosurgery programs.
Virginia M. Diavolitsis, MD, is employed by Riverside Radiation Oncology, Inc. She is a Partner with The Ohio State University.
Sara Hardy, MD, MS, is employed by University of Rochester Medical Center.
Raju Raval, MD, DPhil, is employed by The Ohio State University Wexner Medical Center. Dr. Raval receives honoraria from Varian Medical Systems. Dr. Raval serves as a Core Committee Member with the NRG Clinical Trials Group and is Associate Editor of the Tumor Section of Neurosurgery (Journal).
Roshan S. Prabhu, MD, MS, is employed by Southeast Radiation Oncology Group, Levine Cancer Institute.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.